Identification and Impact of Vaginal Flora Anomalies Among Pregnant Woman

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

1000 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-07-31

Study Completion Date

2013-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective multicentric study including six clinical units of Gynecology and Obstetrics (5 public health hospital and one private team), one research team in clinical microbiology and one Center of Clinical investigation (CIC).

There is a correlation between premature delivery and bacterial vaginosis. So, the anomalies of vaginal flora are a potential target for the campaign against prematurity.

The main objective of this study is to achieve an objective and reproducible technique of identification and quantification by molecular biology of lactobacilla and all the other micro-organisms involved in vaginal flora anomalies.

The secondary objectives are the exhaustive culture of bacteria, the characterisation of intermediate vaginal flora and bacterial vaginosis among pregnant woman by PCR targeting the ribosomic ADN 16S coupled with clonage techniques.

The number of patient to include is 1000 (time of inclusions: 24 months). The vaginal smears will be realized until 32 weeks of gestation (Max: 3 taking of vaginal smears by patient).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Bacterial Vaginosis Carriage in Early Pregnancy and Preterm Delivery in Martinique, F.W.I

NCT03303859

Bacterial Vaginosis

COMPLETED

Real-Time PCR for the Detection of Vaginal Group B Streptococcus Carriage: a Medico-Economic Study

NCT00920530

Neonatal Infections Streptococcus Agalactiae

COMPLETED

Medico-economic Impact of Screening Atopobium Vaginae and Gardnerella Vaginalis in Molecular Biology by "Point-of-care" During Pregnancy

NCT02288832

Low Risk of Preterm Delivery

COMPLETED PHASE2/PHASE3

Colonization with Group B Streptococcus During Pregnancy

NCT03671486

Gestational Mother Streptococcus Agalactiae Infection

COMPLETED

Vaginal, Placental and Neonatal Buccal Mycobiota and Microbiome in Preterm Birth

NCT04165252

Preterm Birth Microbial Colonization

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vaginosis, Bacterial

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

cervical smear

biological analysis

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Pregnant patients aged more than 18 years and more than 14 weeks of gestation but less than 28 weeks.
* Multiple pregnancy won't be included.
* Patient with a risk of premature delivery with a short cervix or a cervix measured at less than 25 mm (measure done by vaginal ultrasound of the cervix).
* Or patient with a past of premature delivery and/or of late abortion.
* Symptomatic or asymptomatic patient.
* Patients consulting for pregnancy follow up or hospitalized in a unit of Gynecology and Obstetrics involved in the study.
* social security cover
* written informed consent

Exclusion Criteria

* antecedents : treated hypertension, Foetal malformation, APLS known, diabetes, renal disease, SLE
* treated with antibiotics the inclusion's day
* dropping consent.

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No